Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.87% | -28.71% | -44.85% | -145.65% | 214.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.87% | -28.71% | -44.85% | -145.65% | 214.89% |
| Cost of Revenue | -29.74% | -35.96% | -39.75% | -82.06% | 42.58% |
| Gross Profit | 1.83% | -26.20% | -46.27% | -527.88% | 172.59% |
| SG&A Expenses | 14.96% | 1.64% | 27.26% | -1.52% | -7.79% |
| Depreciation & Amortization | -10.57% | -13.18% | -13.18% | -12.41% | -47.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.99% | -16.93% | 38.93% | -4.59% | -23.73% |
| Operating Income | -19.89% | 7.39% | -200.03% | -22.86% | 68.58% |
| Income Before Tax | 51.19% | 74.01% | -56.14% | 107.52% | 67.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.19% | 74.01% | -56.14% | 107.54% | 67.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.19% | 74.01% | -56.14% | 107.54% | 67.10% |
| EBIT | -19.89% | 7.39% | -200.03% | -22.86% | 68.58% |
| EBITDA | -42.27% | 4.46% | -565.37% | -33.01% | 75.82% |
| EPS Basic | 81.28% | 69.22% | -154.43% | -3.25% | 57.36% |
| Normalized Basic EPS | 89.47% | 92.55% | 31.46% | 44.27% | 30.19% |
| EPS Diluted | 81.28% | 69.22% | -154.43% | -3.25% | 57.36% |
| Normalized Diluted EPS | 89.47% | 92.55% | 31.46% | 44.27% | 30.19% |
| Average Basic Shares Outstanding | 363.76% | 248.89% | 127.75% | 14.57% | 2.47% |
| Average Diluted Shares Outstanding | 363.76% | 248.89% | 127.75% | 14.57% | 2.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
